AbbVie Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-79.7% vs price
Base Case (Median)
-62.2% vs price
Bull Case (75th pct.)
-55.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-633.80 | -384.9% | High (40%) |
| PE Comparable | $45.22 | -79.7% | Medium (25%) |
| EV/EBITDA | $99.02 | -55.5% | Medium (20%) |
| EV/FCF | $234.39 | 5.4% | Medium (20%) |
| Earnings Power Value | $84.00 | -62.2% | Medium (50%) |
Based on 5 out of 8 methods, ABBV appears overvalued at the current price of $222.47. The base case fair value of $84.00 implies 62.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.